Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.64 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.64 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.44 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.44 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2149269 | 0.89 | CYP1A1 (0.65) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL10995137 | 0.83 | CYSLTR1 (0.63) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL2149705 | 0.83 | CYP1A1 (0.70) | CYP1A2CYP1A1CYP1B1CYP2C19CYP3A4 | |
| SCHEMBL10988521 | 0.83 | CYP1A1 (0.63) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL10992543 | 0.81 | TP53 (0.54) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL10993460 | 0.80 | CYP1A1 (0.59) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL10991389 | 0.79 | CYP1A1 (0.60) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL10993972 | 0.79 | CYP1A1 (0.64) | CYP1A2CYP1A1CYP1B1CYSLTR1CYP2C19 | |
| SCHEMBL12219997 | 0.78 | CYP1A1 (0.55) | CYP1A2CYP1A1CYP1B1CYSLTR1KDM4E | |
| SCHEMBL2149270 | 0.78 | CYP1A1 (0.52) | CYP1A2CYP1A1CYP1B1PRKDCKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105198872-A | Chromenone analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2015-12-30 | — | — | CN | disclosed |
| CN-102227417-B | Chromenone analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2015-09-16 | — | — | CN | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GlaxoSmithKline, LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| US-8987258-B2 | Chromenone analogs as sirtuin modulators | GLAXOSMITHKLINE LLC | 2015-03-24 | — | — | US | disclosed |
| EP-2342188-B1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2342188-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010037127-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257174-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A2 1857/4885CYP1A1 1724/4885CYP1B1 1112/4885 |
| US-20150148343-A1 | CHROMENONE ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CYP1A2 1508/4885CYP1A1 1534/4885CYP1B1 928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.